Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Edwards Lifesciences Reports Fourth Quarter Results
February 1, 2017 4:15 PM ESTIRVINE, Calif., Feb. 1, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2016.Â
Fourth Quarter and Recent Highlights:
Sales grew 14 percent to $768 million; underlying1 sales were up 15 percent Global Transcatheter Heart Valve Therapy (THVT) sales grew 29 percent to $432 million U.S. THVT sales were up 38 percent EPS was $0.73, an increase of 14... More